FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740333722> ?p ?o ?g. }

• W2740333722 abstract "ATAD2 (ATPase family AAA-domain containing protein 2, also called ANCCA) is an epigenetic regulator that binds to chromatin through its bromodomain (BD), a motif specialized for acetyl-lysine recognition. ATAD2 directly associates with multiple transcription factors such as ERα, AR, E2F, and Myc; hence, ATAD2 has been proposed to act as a co-factor for oncogenic transcription factors. Furthermore, we have recently reported a novel role for ATAD2 during DNA replication, uncovering interactions between ATAD2 and histone acetylation marks on newly synthesized histone H4. High expression of ATAD2 strongly correlates with poor patient prognosis in multiple tumor types, including gastric, endometrial, hepatocellular, ovarian, breast and lung cancers. However, the exact function of ATAD2 in these tumor types remains unclear. A more thorough validation of ATAD2 as a therapeutic target is hampered by the lack of isoform-selective, potent and cellularly active ATAD2 inhibitors. A systematic assessment of crystal structures of BD-containing protein family predicted that development of selective inhibitors of ATAD2 would be challenging. In line with this prediction, only limited progress in developing lead compounds targeting ATAD2 has been reported so far. A few notable exceptions relied on fragments as starting points, however, their weak potency, insufficient selectivity against other BDs, permeability limitations or modest cellular activity have curbed their further development towards drug candidates. Here we embarked on a novel strategy to identify ATAD2 inhibitors: 11 different DNA-encoded libraries adding up to 67 billion unique encoded compounds were combined and incubated with ATAD2 BD followed by two rounds of affinity-mediated selection. This approach provided with several series of binders, for which specific target engagement of their SMOL moiety upon off-DNA synthesis was confirmed in biochemical and biophysical assays. Several rounds of potency optimization led to the identification of BAY-850, a highly potent and ATAD2 (isoform A) mono-selective inhibitor, which holds an amine substituted 3-(2-furyl)benzamide core. This compound shows - as revealed by size exclusion chromatography and native mass spectrometry - a novel mode of action for a BD inhibitor based on specific target dimerization. In a cellular fluorescence recovery after photobleaching (FRAP) assay BAY-850 displaced wild-type ATAD2 from the chromatin to the same extent as the genetic mutagenesis of ATAD2 BD. In contrast, chemically very similar inactive control compounds showed no major effects on ATAD2 association with the chromatin. These results qualify BAY-850 as the first biologically active ATAD2 isoform A-specific chemical probe, which will enable further elucidation of the cancer biology of this intriguing protein. Citation Format: Amaury E. Fernandez-Montalvan, Markus Berger, Benno Kuropka, Seong Joo Koo, Volker Badock, Joerg Weiske, Simon J. Holton, Apirat Chaikuad, Laura Diaz-Saez, James Bennett, Oleg Federov, Kilian Huber, Paolo Centrella, Matthew A. Clark, Christoph E. Dumelin, Eric A. Sigel, Holly S. Soutter, Dawn M. Troast, Ying Zhang, John W. Cuozzo, Anthony D. Keefe, Didier Roche, Vincent Rodeschini, Jan Hubner, Hilmar Weinmann, Ingo V. Hartung, Matyas Gorjanacz. Potent and isoform-selective ATAD2 bromodomain inhibitor with unprecedented chemical structure and mode of action [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5084. doi:10.1158/1538-7445.AM2017-5084" @default.
• W2740333722 created "2017-08-08" @default.
• W2740333722 creator A5000161986 @default.
• W2740333722 creator A5000986077 @default.
• W2740333722 creator A5002212329 @default.
• W2740333722 creator A5002912000 @default.
• W2740333722 creator A5005846081 @default.
• W2740333722 creator A5005847343 @default.
• W2740333722 creator A5010855100 @default.
• W2740333722 creator A5014473827 @default.
• W2740333722 creator A5017336785 @default.
• W2740333722 creator A5020274297 @default.
• W2740333722 creator A5024172426 @default.
• W2740333722 creator A5030400947 @default.
• W2740333722 creator A5038543877 @default.
• W2740333722 creator A5042719210 @default.
• W2740333722 creator A5042973046 @default.
• W2740333722 creator A5043696940 @default.
• W2740333722 creator A5064686912 @default.
• W2740333722 creator A5066085816 @default.
• W2740333722 creator A5067338320 @default.
• W2740333722 creator A5073508039 @default.
• W2740333722 creator A5075097409 @default.
• W2740333722 creator A5080918750 @default.
• W2740333722 creator A5083278176 @default.
• W2740333722 creator A5083840314 @default.
• W2740333722 creator A5087539778 @default.
• W2740333722 creator A5087947375 @default.
• W2740333722 creator A5091709028 @default.
• W2740333722 date "2017-07-01" @default.
• W2740333722 modified "2023-09-26" @default.
• W2740333722 title "Abstract 5084: Potent and isoform-selective ATAD2 bromodomain inhibitor with unprecedented chemical structure and mode of action" @default.
• W2740333722 doi "https://doi.org/10.1158/1538-7445.am2017-5084" @default.
• W2740333722 hasPublicationYear "2017" @default.
• W2740333722 type Work @default.
• W2740333722 sameAs 2740333722 @default.
• W2740333722 citedByCount "0" @default.
• W2740333722 crossrefType "proceedings-article" @default.
• W2740333722 hasAuthorship W2740333722A5000161986 @default.
• W2740333722 hasAuthorship W2740333722A5000986077 @default.
• W2740333722 hasAuthorship W2740333722A5002212329 @default.
• W2740333722 hasAuthorship W2740333722A5002912000 @default.
• W2740333722 hasAuthorship W2740333722A5005846081 @default.
• W2740333722 hasAuthorship W2740333722A5005847343 @default.
• W2740333722 hasAuthorship W2740333722A5010855100 @default.
• W2740333722 hasAuthorship W2740333722A5014473827 @default.
• W2740333722 hasAuthorship W2740333722A5017336785 @default.
• W2740333722 hasAuthorship W2740333722A5020274297 @default.
• W2740333722 hasAuthorship W2740333722A5024172426 @default.
• W2740333722 hasAuthorship W2740333722A5030400947 @default.
• W2740333722 hasAuthorship W2740333722A5038543877 @default.
• W2740333722 hasAuthorship W2740333722A5042719210 @default.
• W2740333722 hasAuthorship W2740333722A5042973046 @default.
• W2740333722 hasAuthorship W2740333722A5043696940 @default.
• W2740333722 hasAuthorship W2740333722A5064686912 @default.
• W2740333722 hasAuthorship W2740333722A5066085816 @default.
• W2740333722 hasAuthorship W2740333722A5067338320 @default.
• W2740333722 hasAuthorship W2740333722A5073508039 @default.
• W2740333722 hasAuthorship W2740333722A5075097409 @default.
• W2740333722 hasAuthorship W2740333722A5080918750 @default.
• W2740333722 hasAuthorship W2740333722A5083278176 @default.
• W2740333722 hasAuthorship W2740333722A5083840314 @default.
• W2740333722 hasAuthorship W2740333722A5087539778 @default.
• W2740333722 hasAuthorship W2740333722A5087947375 @default.
• W2740333722 hasAuthorship W2740333722A5091709028 @default.
• W2740333722 hasConcept C104317684 @default.
• W2740333722 hasConcept C119157956 @default.
• W2740333722 hasConcept C185592680 @default.
• W2740333722 hasConcept C2779634854 @default.
• W2740333722 hasConcept C41091548 @default.
• W2740333722 hasConcept C502942594 @default.
• W2740333722 hasConcept C54355233 @default.
• W2740333722 hasConcept C552990157 @default.
• W2740333722 hasConcept C64927066 @default.
• W2740333722 hasConcept C70721500 @default.
• W2740333722 hasConcept C74401373 @default.
• W2740333722 hasConcept C83640560 @default.
• W2740333722 hasConcept C86339819 @default.
• W2740333722 hasConcept C86803240 @default.
• W2740333722 hasConcept C95444343 @default.
• W2740333722 hasConceptScore W2740333722C104317684 @default.
• W2740333722 hasConceptScore W2740333722C119157956 @default.
• W2740333722 hasConceptScore W2740333722C185592680 @default.
• W2740333722 hasConceptScore W2740333722C2779634854 @default.
• W2740333722 hasConceptScore W2740333722C41091548 @default.
• W2740333722 hasConceptScore W2740333722C502942594 @default.
• W2740333722 hasConceptScore W2740333722C54355233 @default.
• W2740333722 hasConceptScore W2740333722C552990157 @default.
• W2740333722 hasConceptScore W2740333722C64927066 @default.
• W2740333722 hasConceptScore W2740333722C70721500 @default.
• W2740333722 hasConceptScore W2740333722C74401373 @default.
• W2740333722 hasConceptScore W2740333722C83640560 @default.
• W2740333722 hasConceptScore W2740333722C86339819 @default.
• W2740333722 hasConceptScore W2740333722C86803240 @default.
• W2740333722 hasConceptScore W2740333722C95444343 @default.
• W2740333722 hasLocation W27403337221 @default.
• W2740333722 hasOpenAccess W2740333722 @default.
• W2740333722 hasPrimaryLocation W27403337221 @default.
• W2740333722 hasRelatedWork W1973997212 @default.
• W2740333722 hasRelatedWork W2063339877 @default.

• next